Compare Amphastar Pharmaceuticals Inc (AMPH) vs Salesforce Inc (CRM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Salesforce Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Salesforce Inc trades at $196.95 (market cap $161.76B). The key difference: Salesforce Inc is far larger — about 187.2× Amphastar Pharmaceuticals Inc's market cap, and Salesforce Inc pays a 0.89% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | CRM | |
|---|---|---|
Market Cap | $863.95M | $161.76B |
Sector | Health | Technology |
52-Week High | $30.81 | $266.23 |
52-Week Low | $16.87 | $150.12 |
Enterprise Value | $1.26B | $191.81B |
Dividend Yield | — | 0.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Salesforce (CRM) trades at $197.51, up 2.47% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $3.88 exceeding expectations of $3.13. Revenue growth accelerated to $37.90 billion in 2025, while net income margin improved to 16.35%. Analyst consensus remains strongly bullish with a $230.61 price target.
Outlook: Salesforce demonstrates robust fundamentals with high profitability and consistent earnings outperformance, supported by AI monetization growth. Risks include competitive pressures in SaaS and macroeconomic volatility affecting tech stocks. The stock offers potential upside to analyst targets if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →
